La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ashland a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ashland..

Ashland (NYSE:ASH) Azioni, Catena delle Opzioni

Ashland

Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.

Ashland Global Holdings

Ashland Inc

Ashtrom Group Ltd

ASBERRY 22 HLDGS INC by ASBERRY 22 HLDGS INC.

Asberry 22 Holdings Inc

ASHLEY SVCS GROUP LTD by ASHLEY SVCS GROUP LTD.

Ashley Services Group Ltd

Xtrackers Harvest CSI 300 China A-Shares ETF

Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF

Ashtead Group PLC

ASHTED GRP PLC UNSP/ADR by Ashtead Group PLC

DBX ETF Trust Xtrackers MSCI China A Inclusion Equity ETF

PROGRESSIVE PLANET NEW by Progressive Planet Solutions Inc.

Progressive Planet Solutions Inc

WIIM

AVNT

AXTA

CENX

MATV

MEOH

MTUS

PACK

TANH

TROX

Shares of companies within the broader materials sector are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A decrease of trade tensions could reduce demand uncertainty for materials.

The board of directors of Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock which represents a 2.5 percent increase from the previous quarter. The dividend will be payable on June 15, 2025, to stockholders of record at the close of business on June 1, 2025.
As of April 30, 2025, there were 45,696,225 shares of Ashland common stock outstanding.

News

Dividends

Ashland Increases Quarterly Dividend From $0.41 To $0.415 Per Share

JP Morgan analyst Jeffrey Zekauskas maintains Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) with a Overweight and lowers the price target from $71 to $67.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Ashland, Lowers Price Target to $67

Today the company's board of directors appointed William C. Whitaker, vice president, finance, and director, investor relations, to serve as the company's interim chief financial officer until the board concludes its review process. &nbsp;

Management

Ashland Appoints William C. Whitaker, Vice President, Finance, And Director, Investor Relations, To Serve As The Company's Interim CFO Until The Board Concludes Its Review Process

Ashland's Senior Vice President And Chief Financial Officer Kevin Willis To Depart From The Company, Effective May 16th

Ashland shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY25 sales guidance. Also, UBS cut its price target on the stock from $85 to $74.

UBS analyst Joshua Spector maintains Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) with a Buy and lowers the price target from $85 to $74.

UBS Maintains Buy on Ashland, Lowers Price Target to $74

Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) lowers FY2025 sales outlook from $1.90 billion-$2.05 billion to $1.82 billion-$1.90 billion vs $1.93 billion estimate.

Guidance

Ashland Lowers FY2025 Sales Guidance from $1.90B-$2.05B to $1.82B-$1.90B vs $1.93B Est

Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) reported quarterly earnings of $0.99 per share which missed the analyst consensus estimate of $1.10 by 10 percent. This is a 22.05 percent decrease over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $479.00 million which missed the analyst consensus estimate of $502.65 million by 4.71 percent. This is a 16.70 percent decrease over sales of $575.00 million the same period last year.

Earnings

Earnings Misses

Ashland Q2 Adj. EPS $0.99 Misses $1.10 Estimate, Sales $479.00M Miss $502.65M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Wells Fargo analyst Michael Sison maintains Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) with a Overweight and lowers the price target from $69 to $58.

Wells Fargo Maintains Overweight on Ashland, Lowers Price Target to $58

The investment significantly expands Ashland's pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and Brazil. Between 2019 and 2023 the consumption of coated tablets in Latin America had an average growth of 4.3 percent per year, while Brazil has reached growth of 5.7 percent per year+.&nbsp;
The investment also includes the modernization of equipment for microbial protection in personal care applications at the Research and Development (R&amp;D) laboratory of the company's Technical Center in São Paulo and follows the company's previous investments to expand their bioresorbable polymers facility in Mullingar, Ireland and biofunctionals R&amp;D lab in Shanghai, China. &nbsp;

Ashland Invests $10M In Brazil Expansion, Boosting Pharmaceutical And Personal Care Capabilities

Wells Fargo analyst Michael Sison maintains Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) with a Overweight and lowers the price target from $80 to $69.

Wells Fargo Maintains Overweight on Ashland, Lowers Price Target to $69

Ashland shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $68 to $71.

U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Wednesday.
Shares of Paychex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) rose sharply during Wednesday's session after the company reported <a href="https://in.benzinga.com/25/03/44494897/paychex-shares-gain-on-q3-earnings-beat">better-than-expected quarterly adjusted EPS.</a>
The company reported third-quarter revenue growth of 5% year-on-year to $1.509 billion, marginally missing the analyst consensus estimate of $1.516 billion. Adjusted EPS of $1.49 beat the consensus estimate of $1.48.
Paychex shares jumped 5.5% to $152.02 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Playtika Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) shares jumped 23.2% to $5.42.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) gained 18.4% to $49.31 as the company posted better-than-expected earnings for the third quarter.</li>
<li>Perimeter Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRM#NYSE">PRM</a>) rose 15% to $10.48 after UBS upgraded the stock from Neutral to Buy and announced a price target of $14.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) gained 14.3% to $29.05 after the company reported better-than-expected quarterly adjusted EPS and announced its board approved an update to its investment policy to add Bitcoin as a treasury reserve asset.</li>
<li>Super Hi International Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) gained 10.6% to $24.47 following fourth-quarter results.</li>
<li>BRP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) gained 9.9% to $39.06 following better-than-expected quarterly earnings.</li>
<li>Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) surged 9.6% to $212.18 following better-than-expected quarterly earnings.</li>
<li>JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) gained 7.8% to $22.33 following fourth-quarter results.</li>
<li>Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) rose 5.7% to $60.16. JP Morgan analyst Jeffrey Zekauskas upgraded Ashland from Neutral to Overweight and raised the price target from $68 to $71.</li>
<li>Weatherford International plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) rose 4.7% to $57.41.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44492633/jim-cramer-palantir-is-a-winner-recommends-selling-this-tech-stock">Jim Cramer: Palantir Is A &#8216;Winner,&#8217; Recommends Selling This Tech Stock</a></li>
</ul>
Image: Shutterstock

Intraday Update

Markets

Movers

Trading Ideas

CTAS

DOOO

PAYX

PLTK

WFRD

Paychex Posts Better-Than-Expected Earnings, Joins Worthington Enterprises, GameStop, Cintas And Other Big Stocks Moving Higher On Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Catherine Ramsey upgraded the rating for Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Neutral to Outperform and raised the price target from $396 to $407. Waters shares closed at $368.53 on Tuesday. <a href="https://www.benzinga.com/quote/wat/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Timothy Switzer upgraded ConnectOne Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) from Market Perform to Outperform and raised the price target from $31 to $32. ConnectOne Bancorp shares closed at $23.73 on Tuesday. <a href="https://www.benzinga.com/quote/CNOB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Devin McDermott upgraded the rating for Range Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Underweight to Equal-Weight and increased the price target from $40 to $49. Range Resources shares closed at $40.14 on Tuesday. <a href="https://www.benzinga.com/quote/rrc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst James Faucette upgraded Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) from Equal-Weight to Overweight but lowered the price target from $55 to $46. Global E Online shares closed at $38.26 on Tuesday. <a href="https://www.benzinga.com/quote/GLBE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas upgraded Ashland Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) from Neutral to Overweight and raised the price target from&nbsp;$68&nbsp;to&nbsp;$71. Ashland shares closed at $56.93 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Image: Shutterstock

Upgrades

Pre-Market Outlook

AKYA

CNOB

GLBE

This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Across the recent three months, 4 analysts have shared their insights on Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.0, a high estimate of $93.00, and a low estimate of $68.00. A decline of 6.59% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1742990494_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Ashland by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ashland. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ashland compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ashland's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Ashland's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ashland analyst ratings.</a>
<h2>All You Need to Know About Ashland</h2>
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
<h3>Financial Milestones: Ashland's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ashland's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -14.38%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Ashland's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -40.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.04%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ashland's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ashland's debt-to-equity ratio is below the industry average at 0.55, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Ashland Through The Eyes Of 4 Analysts

JP Morgan analyst Jeffrey Zekauskas upgrades Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) from Neutral to Overweight and raises the price target from $68 to $71.

JP Morgan Upgrades Ashland to Overweight, Raises Price Target to $71

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $83.0, a high estimate of $93.00, and a low estimate of $68.00. A decline of 6.53% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741183223_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Ashland among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$84.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ashland. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ashland compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ashland's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Ashland's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ashland analyst ratings.</a>
<h2>Get to Know Ashland Better</h2>
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
<h3>Ashland: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Ashland's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -14.38% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Ashland's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -40.74%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Ashland's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.04%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ashland's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.55.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Ashland Stands With Analysts

Seaport Global analyst Michael Harrison downgrades Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) from Buy to Neutral.

Downgrades

Seaport Global Downgrades Ashland to Neutral

Press Releases

Ashland board authorizes quarterly dividend

Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025

Ashland completes sale of Avoca business to Mane

Ashland to host 2025 Innovation Day for analysts and investors

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest

Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast

Ashland reports second quarter fiscal 2025 results and revises full-year outlook

Comments

Ashland

Ashland (ASH) Opzioni

Ashland (NYSE:ASH) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO